Talon soars 28.8% on FDA SPA on Phase III leukaemia study
This article was originally published in Scrip
Executive Summary
Shares of Talon Therapeutics jumped 28.8% on 29 August on the news that the company had reached a special protocol assessment (SPA) agreement with the US FDA for the design of a Phase III study for Marqibo (vincristine sulfate liposomes injection) testing the drug in adults with newly diagnosed Philadelphia chromosome negative (Ph-) acute lymphoblastic leukaemia (ALL).